Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.42 |
| ▸ | CSNK1D | P48730 | 5/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5141049 | 0.87 | GAA (0.43) | ADORA3KDM4EALDH1A1HSD17B10HPGD | |
| SCHEMBL14209188 | 0.84 | MEN1 (0.47) | ADORA3KDM4ENPC1RAB9AALDH1A1 | |
| SCHEMBL4504079 | 0.83 | CACNA1B (0.45) | KDM4ENPC1RAB9AALDH1A1HSD17B10 | |
| SCHEMBL4493009 | 0.82 | SMN1; SMN2 (0.47) | NPC1RAB9AALDH1A1GAAL3MBTL1 | |
| SCHEMBL4495523 | 0.81 | TNKS (0.39) | KDM4ERAB9AALDH1A1HSD17B10HPGD | |
| SCHEMBL4509541 | 0.78 | KDM4E (0.47) | KDM4ECSNK1DRAB9AALDH1A1HSD17B10 | |
| SCHEMBL4489203 | 0.75 | ALDH1A1 (0.49) | KDM4ECSNK1DNPC1RAB9AALDH1A1 | |
| SCHEMBL4510611 | 0.75 | KDM4E (0.45) | ADORA3KDM4ERAB9AALDH1A1HSD17B10 | |
| SCHEMBL4500744 | 0.75 | CSNK1D (0.39) | KDM4ECSNK1DNPC1RAB9AALDH1A1 | |
| SCHEMBL4496814 | 0.74 | KDM4E (0.43) | KDM4ERAB9AALDH1A1HSD17B10HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7569580-B2 | Tetrazolo[1,5-a]thieno[2,3-e]pyridine-4-carboxylic acid | RIGEL PHARMACEUTICALS, INC. (US) | 2009-08-04 | — | — | US | disclosed |
| US-7569580-B2 | Tetrazolo[1,5-a]thieno[2,3-e]pyridine-4-carboxylic acid | RIGEL PHARMACEUTICALS, INC. (US) | 2009-08-04 | — | — | US | disclosed |
| US-7569580-B2 | Tetrazolo[1,5-a]thieno[2,3-e]pyridine-4-carboxylic acid | RIGEL PHARMACEUTICALS, INC. (US) | 2009-08-04 | — | — | US | disclosed |
| US-7358259-B2 | Tetrazoloquinoline, triazoloquinoline, and oxazoloquinoline compounds, e.g., 9-chloro-N-isopropoxytetrazolo[1,5-a]quinoline-4-carboxamide | RIGEL PHARMACEUTICALS, INC. (US) | 2008-04-15 | — | — | US | disclosed |
| US-7358259-B2 | Tetrazoloquinoline, triazoloquinoline, and oxazoloquinoline compounds, e.g., 9-chloro-N-isopropoxytetrazolo[1,5-a]quinoline-4-carboxamide | RIGEL PHARMACEUTICALS, INC. (US) | 2008-04-15 | — | — | US | disclosed |
| US-7358259-B2 | Tetrazoloquinoline, triazoloquinoline, and oxazoloquinoline compounds, e.g., 9-chloro-N-isopropoxytetrazolo[1,5-a]quinoline-4-carboxamide | RIGEL PHARMACEUTICALS, INC. (US) | 2008-04-15 | — | — | US | disclosed |
| US-20070149520-A1 | HCV Inhibitors And Methods Of Using Them | RIGEL PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070149520-A1 | HCV Inhibitors And Methods Of Using Them | RIGEL PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070149520-A1 | HCV Inhibitors And Methods Of Using Them | RIGEL PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-20050282850-A1 | Heterotricylic compounds for use as HCV inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149520-A1 | HCV Inhibitors And Methods Of Using Them | HAVCR2, GLS2, EIF2AK2 | ADORA3 3686/4885KDM4E 3202/4885CSNK1D 2284/4885 |
| US-20050282850-A1 | Heterotricylic compounds for use as HCV inhibitors | HAVCR2, PYGL, HCCS | ADORA3 2930/4885KDM4E 4239/4885CSNK1D 1403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.